Table 1 Patient TNFi therapy exposure and bDMARD switching
All (n = 2795) | North America (n = 530) | LatAm (n = 137) | EU5 (n = 1478) | APAC (n = 335) | T&ME (n = 315) | |
|---|---|---|---|---|---|---|
Number of previous TNFi therapies ever received, n (%) | ||||||
0 | 916 (32.8) | 108 (20.4) | 15 (10.9) | 535 (36.2) | 103 (30.7) | 155 (49.2) |
1 | 1623 (58.1) | 347 (65.5) | 113 (82.5) | 821 (55.5) | 194 (57.9) | 148 (47.0) |
2 | 200 (7.2) | 60 (11.3) | 9 (6.6) | 89 (6.0) | 31 (9.3) | 11 (3.5) |
3+ | 56 (2.0) | 15 (2.8) | 0 (0.0) | 33 (2.2) | 7 (2.1) | 1 (0.3) |
Time on 1st bDMARD despite primary lack of efficacy, months | (n = 34) | (n = 16) | (n = 13) | (n = 2) | (n = 3) | |
Mean (SD) | 11.1 (10.2) | 12.6 (11.6) | – | 10.7 (9.7) | 1 (0.0) | 11.3 (5.0) |
Median | 9.5 | 11.0 | – | 9.0 | 1.0 | 12.0 |
Min, Max | 0.0–36.0 | 2.0–36.0 | – | 0.0–36.0 | 1.0–1.0 | 6.0–16.0 |
IQR | 0.0, 1.0 | 0.0, 1.5 | 0.0, 0.0 | 0.0, 1.0 | 0.0, 0.5 | 0.0, 0.0 |